Log in to save to my catalogue

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spina...

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spina...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_15c4bb3f54a24e75bc25f097944bb5f3

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment

About this item

Full title

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment

Publisher

England: BioMed Central Ltd

Journal title

Orphanet journal of rare diseases, 2024-09, Vol.19 (1), p.344-11, Article 344

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Spinal muscular atrophy type 1 (SMA1) is the most severe and early form of SMA, a genetic disease with motor neuron degeneration. Onasemnogene abeparvovec gene transfer therapy (GT) has changed the natural history of SMA1, but real-world data are scarce.
A French national expert committee identified 95 newly diagnosed treatment-naive SMA1 patien...

Alternative Titles

Full title

Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_15c4bb3f54a24e75bc25f097944bb5f3

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_15c4bb3f54a24e75bc25f097944bb5f3

Other Identifiers

ISSN

1750-1172

E-ISSN

1750-1172

DOI

10.1186/s13023-024-03326-3

How to access this item